Putative Clinical Potential of <i>ERBB2</i> Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients

Putative Clinical Potential of <i>ERBB2</i> Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients

Anti-HER2 monoclonal antibody trastuzumab improves the survival of those patients with advanced gastroesophageal adenocarcinoma (GEA) exhibiting HER2/<i>ERBB2</i> overexpression/amplification. The current gold standard methods used to diagnose the HER2 status in GEA are immunohistochemis...

Full description

Bibliographic Details
Main Authors: Elisa Boldrin, Marcodomenico Mazza, Maria Assunta Piano, Rita Alfieri, Isabella Monia Montagner, Giovanna Magni, Maria Chiara Scaini, Loretta Vassallo, Antonio Rosato, Pierluigi Pilati, Antonio Scapinello, Matteo Curtarello
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
liquid biopsy
cell-free DNA (cfDNA)
HER2
<i>ERBB2</i>
gastroesophageal adenocarcinoma
droplet digital PCR (ddPCR)
Online Access:https://www.mdpi.com/2072-6694/14/9/2180

Internet

https://www.mdpi.com/2072-6694/14/9/2180

Similar Items